Safety and Effectiveness of Adriamycin and Cyclophosphamide Followed by Dose Dense (Every 2 Weeks) Paclitaxel Given With Trastuzumab as Neoadjuvant Treatment in HER2-Positive Early-Stage Breast Cancer
Clinical Breast Cancer · 2025
DOI: 10.1016/j.clbc.2025.04.017 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Breast Cancer, 2025. Verfasst von Yael Berner-Wygoda und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre and the University of Toronto, Toronto, Ontario, C…. Hauptthemen laut MEDLINE: Breast Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Neoadjuvant Therapy. Die Arbeit nennt 12 Literaturangaben. Gefördert von: University Health Network.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre and the University of Toronto, Toronto, Ontario, Canada. Electronic address: yael.berner-wygoda@uhn.ca.
- Department of Medicine, Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre and the University of Toronto, Toronto, Ontario, Canada.
- Department of Kinesiology and Physical activity, Faculty of education, McGill University, Quebec, Canada.
- Gerald Bronfman Department of Oncology, St. Mary's Hospital Center, McGill University, Montréal, Quebec, Canada.
Förderung
- University Health Network
Zitieren
APA
Berner-Wygoda, Y., Li, M., Perlon, C., Malon, D., Pathak, N., Di Iorio, M., Savill, J., Aljuhani, A., Nadler, M. B., & Amir, E. (2025). Safety and Effectiveness of Adriamycin and Cyclophosphamide Followed by Dose Dense (Every 2 Weeks) Paclitaxel Given With Trastuzumab as Neoadjuvant Treatment in HER2-Positive Early-Stage Breast Cancer. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2025.04.017
Vancouver
Berner-Wygoda Y, Li M, Perlon C, Malon D, Pathak N, Di Iorio M, et al. Safety and Effectiveness of Adriamycin and Cyclophosphamide Followed by Dose Dense (Every 2 Weeks) Paclitaxel Given With Trastuzumab as Neoadjuvant Treatment in HER2-Positive Early-Stage Breast Cancer. Clinical Breast Cancer. 2025. doi:10.1016/j.clbc.2025.04.017
BibTeX
@article{BernerWygoda2025,
author = {Berner-Wygoda, Yael and Li, Meredith and Perlon, Chloe and Malon, Diego and Pathak, Neha and Di Iorio, Massimo and Savill, Jacqueline and Aljuhani, Amal and Nadler, Michelle B and Amir, Eitan},
title = {Safety and Effectiveness of Adriamycin and Cyclophosphamide Followed by Dose Dense (Every 2 Weeks) Paclitaxel Given With Trastuzumab as Neoadjuvant Treatment in HER2-Positive Early-Stage Breast Cancer},
journal = {Clinical Breast Cancer},
year = {2025},
doi = {10.1016/j.clbc.2025.04.017}
}
EUVIMED